QPPV.COM KNOWLEDGE ASSESSMENT

Palivizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Palivizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which pharmacological feature most directly explains the traditional monthly dosing schedule during periods of RSV circulation?

The antibody must be administered monthly to maintain continuous stimulation of T cells The antibody is rapidly converted into a vaccine after each injection Circulating antibody concentrations decline, so repeated doses help maintain protective exposure RSV changes its host receptor every month and therefore requires a new antibody dose

Question 2 of 10 Which approach is most appropriate for aggregate analysis of breakthrough RSV cases?

Combine all cases without regard to eligibility, dosing or procedures Analyse cases separately from adverse drug reactions and stratify by eligibility, dose completeness and major cardiac procedures Count only cases with confirmed resistance mutations Exclude cases occurring after the first dose because they cannot be informative

Question 3 of 10 Which operational practice best supports reconstruction of seasonal palivizumab exposure?

Recording only the most recent injection Recording contemporaneous weight, calculated and administered dose, all seasonal dose dates, product and batch Relying on the caregiver's estimate of the number of injections Recording the child's birth weight without subsequent measurements

Question 4 of 10 Which finding would most strongly support classification of a post-injection event as anaphylaxis rather than an isolated respiratory deterioration in a high-risk infant?

Respiratory deterioration alone in a child with chronic lung disease A temporally related reaction with objective allergic features and respiratory or circulatory compromise Any fever occurring within one week of injection A positive RSV test obtained several days after the injection

Question 5 of 10 Which information is most important for determining whether a child's palivizumab dose was appropriate at the time it was administered?

The child's birth weight only The child's current weight at administration and the calculated dose The average weight of children in the same age group The weight documented at the end of the RSV season

Question 6 of 10 Why is RSV-season context important when evaluating palivizumab exposure and effectiveness?

The medicine is administered only to treat infections that occurred in the previous calendar year Protection is intended during periods of community RSV circulation, so timing of doses and exposure should be interpreted relative to the local season Seasonal context determines whether an injection can cause anaphylaxis RSV season has no relevance once the first dose has been given

Question 7 of 10 Which overall principle should guide the assessment of a palivizumab case?

Treat every event after injection as a direct pharmacological adverse reaction Organise the assessment around eligibility, complete seasonal exposure, event phenotype and infant comorbidity Focus exclusively on viral genotype and disregard dosing history Assess each injection in isolation without considering prior or subsequent doses

Question 8 of 10 Which documentation would be most valuable in a serious suspected hypersensitivity case?

Dose number, reaction latency, allergic features, emergency treatment, hospitalisation and outcome Only the product name and the child's age at birth Only the RSV test result The date of the next planned RSV season

Question 9 of 10 For a report of unusual bruising after intramuscular palivizumab, which follow-up set is most informative?

Platelet count, coagulation status, relevant medicines, injection site, technique and clinical consequences Only the child's RSV subtype Only the time of year and the manufacturer's address The antibody concentration in the general population

Question 10 of 10 How should fever after palivizumab administration generally be approached in pharmacovigilance?

It should automatically be attributed to the injection It should automatically be classified as anaphylaxis Its timing and duration should be assessed alongside RSV, bacterial and other viral evaluations It should be excluded because fever is not relevant in infants

Palivizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings